AVN 63.60 Increased By ▲ 1.85 (3%)
BOP 8.65 Decreased By ▼ -0.08 (-0.92%)
CHCC 124.50 Decreased By ▼ -2.00 (-1.58%)
DCL 8.85 Decreased By ▼ -0.06 (-0.67%)
DGKC 101.70 Decreased By ▼ -0.56 (-0.55%)
EFERT 61.65 Decreased By ▼ -4.90 (-7.36%)
EPCL 42.99 Decreased By ▼ -0.26 (-0.6%)
FCCL 20.40 Decreased By ▼ -0.05 (-0.24%)
FFL 13.67 Increased By ▲ 0.08 (0.59%)
HASCOL 13.39 Decreased By ▼ -0.08 (-0.59%)
HBL 128.88 Increased By ▲ 0.38 (0.3%)
HUBC 79.40 Increased By ▲ 0.54 (0.68%)
HUMNL 7.10 Increased By ▲ 0.72 (11.28%)
JSCL 21.85 Increased By ▲ 0.02 (0.09%)
KAPCO 27.60 Increased By ▲ 0.11 (0.4%)
KEL 3.60 No Change ▼ 0.00 (0%)
LOTCHEM 11.75 Decreased By ▼ -0.03 (-0.25%)
MLCF 36.51 Decreased By ▼ -0.74 (-1.99%)
OGDC 93.80 Increased By ▲ 1.44 (1.56%)
PAEL 30.35 Decreased By ▼ -0.10 (-0.33%)
PIBTL 11.78 Decreased By ▼ -0.01 (-0.08%)
PIOC 83.35 Decreased By ▼ -1.50 (-1.77%)
POWER 9.20 Increased By ▲ 0.05 (0.55%)
PPL 84.45 Increased By ▲ 1.91 (2.31%)
PSO 187.55 Increased By ▲ 1.06 (0.57%)
SNGP 43.00 Increased By ▲ 0.50 (1.18%)
STPL 13.30 No Change ▼ 0.00 (0%)
TRG 51.33 Increased By ▲ 0.23 (0.45%)
UNITY 23.34 Increased By ▲ 0.04 (0.17%)
WTL 0.99 No Change ▼ 0.00 (0%)
BR100 4,113 Increased By ▲ 1.53 (0.04%)
BR30 20,644 Increased By ▲ 22.54 (0.11%)
KSE100 39,762 Increased By ▲ 129.16 (0.33%)
KSE30 16,703 Increased By ▲ 9.81 (0.06%)
Business

Indian drugmaker Biological E. starts human trials of COVID-19 vaccine candidate

  • The trial will test two doses of the vaccine in about 360 healthy subjects aged 18 to 65 years, Biological E. said.
  • India has reported 8.85 million confirmed cases of the virus - the second highest in the world,
16 Nov 2020

BENGALURU: India's Biological E. Ltd has started human trials of its COVID-19 vaccine candidate and expects results by February, the drugmaker said on Monday.

The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate - being developed with Baylor College of Medicine in Houston, Texas, and US-based Dynavax Technologies Corp - after getting the green signal from the Drugs Controller General of India.

The trial will test two doses of the vaccine in about 360 healthy subjects aged 18 to 65 years, Biological E. said.

Separately, Bharat Biotech, a private company developing a vaccine candidate, COVAXIN, with the government-run Indian Council of Medical Research, said it was starting phase III trials on Monday.

India has reported 8.85 million confirmed cases of the virus - the second highest in the world, after the United States - but the number of new daily cases has fallen since a peak in mid-September.

Meanwhile, hopes for a vaccine got a fresh boost after US-based Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial.

Last week, drugmaker Pfizer Inc and German partner BioNTech SE said their vaccine was more than 90% effective.

An Indian government-backed vaccine could be launched as early as February - months earlier than expected - as last-stage trials begin this month, a senior government scientist previously told Reuters.